Paul Laikind is the founder of ViaCyte. ViaCyte has raised $80M in total funding. Latest round: Series D. Backed by Bain Capital Life Sciences.
Paul Laikind is the CEO of ViaCyte, a San Diego-based company focused on developing stem cell-derived cell replacement therapies for insulin-requiring diabetes. The company aims to provide a lasting source of insulin-producing cells to alleviate disease management burdens for diabetics. ViaCyte recently secured an $80 million Series D financing to advance its clinical development.
Full founder directory · Investor directory · Company funding database · Fundraising library